Publisher
Springer Science and Business Media LLC
Subject
Health Informatics,Health Policy,Computer Science Applications
Reference13 articles.
1. U.S. Food and Drug Administration. CDRH’S APPROACH TO TUMOR PROFILING NEXT GENERATION SEQUENCING TESTS. Silver Spring, MD: U.S. Food and Drug Administration; 2017.
https://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/UCM584603.pdf
.
2. FDA. EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets). 2017;:1–57. doi:
https://doi.org/10.1164/rccm.201205-0815OC
.
3. Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18:6373–83.
https://doi.org/10.1158/1078-0432.CCR-12-1627
.
4. Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med. 2016;8:109.
https://doi.org/10.1186/s13073-016-0364-2
.
5. Arango NP, Brusco L, Shaw KRM, Chen K, Eterovic AK, Holla V, et al. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2017;8:41806–14.
https://doi.org/10.18632/oncotarget.16018
.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献